Qiu Fucheng, Gu Ping, Liu Wencong, Li Dong
Department of Neurology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Department of Ultrasound, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Neurol Sci. 2022 Jan;43(1):327-333. doi: 10.1007/s10072-021-05240-z. Epub 2021 Apr 27.
This study aimed to explore the spectrum characteristics of Parkinson's disease (PD) patients with sleep disorders.
This retrospective study included 101 PD patients who received treatment at our hospital between August 2018 and August 2020. According to the modified Hoehn-Yahr (H-Y) classification, the patients were divided into the early-stage (grade I and II) group (N=21), the mid-stage (grade III) group (N=28), and the late-stage (grade IV) groups (N=20). Detailed information including general data and clinical data was collected.
Multivariate logistic regression analysis showed that lower total cholesterol, triglyceride, and uric acid levels were protective factors against the occurrence of sleep disorder, and increased Madopar dosage ≥ 600 mg, Self-rating Anxiety Scale (SAS), and Self-rating Depression Scale (SDS) were risk factors for the occurrence of sleep disorder. The levels of total cholesterol, triglyceride, and uric acid, total sleep time, sleep efficiency, REM sleep latency score, minimum oxygen saturation, and Madopar dosage ≥ 600 mg in the late-stage group were lower than those in the mid-stage group. Meanwhile, homocysteine levels, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, SAS, SDS score, sleep latency score, hypopnea index, the number of times of waking up, and the number of episodes of hypopnea and apnea were higher than those in the mid-stage group.
Decreased levels of total cholesterol, triglyceride, and uric acid were associated with the occurrence of PD. Lower Madopar doses and reducing anxiety and depression might control the occurrence and development of sleep disorders in PD patients.
本研究旨在探讨帕金森病（PD）伴睡眠障碍患者的频谱特征。
本回顾性研究纳入了2018年8月至2020年8月在我院接受治疗的101例PD患者。根据改良的Hoehn-Yahr（H-Y）分级，将患者分为早期（I级和II级）组（N = 21）、中期（III级）组（N = 28）和晚期（IV级）组（N = 20）。收集了包括一般资料和临床资料在内的详细信息。
多因素logistic回归分析显示，总胆固醇、甘油三酯和尿酸水平降低是睡眠障碍发生的保护因素，而美多芭剂量≥600 mg、自评焦虑量表（SAS）和自评抑郁量表（SDS）升高是睡眠障碍发生的危险因素。晚期组的总胆固醇、甘油三酯和尿酸水平、总睡眠时间、睡眠效率、快速眼动睡眠潜伏期评分、最低血氧饱和度以及美多芭剂量≥600 mg均低于中期组。同时，晚期组的同型半胱氨酸水平、匹兹堡睡眠质量指数、爱泼沃斯思睡量表、SAS、SDS评分、睡眠潜伏期评分、呼吸暂停低通气指数、觉醒次数以及呼吸暂停和低通气发作次数均高于中期组。
总胆固醇、甘油三酯和尿酸水平降低与PD的发生有关。降低美多芭剂量以及减轻焦虑和抑郁可能有助于控制PD患者睡眠障碍的发生和发展。
